Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma
- Conditions
- Asthma
- Interventions
- Drug: placeboDrug: ICS/LABA therapyDrug: Salbutamol/albuterolDrug: Levosalbutamol/levalbuterol
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 776
- Registration Number
- NCT01854047
- Locations
- 🇯🇵
Investigational Site Number 392024, Sakai-Shi, Japan
🇯🇵Investigational Site Number 392003, Toride-Shi, Japan
🇯🇵Investigational Site Number 392035, Yokohama-Shi, Japan
Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2013-05-09
- Last Posted Date
- 2014-01-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 61
- Registration Number
- NCT01850680
- Locations
- 🇯🇵
Investigational Site Number 392002, Sendai-Shi, Japan
🇯🇵Investigational Site Number 392001, Sendai-Shi, Japan
Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus
- Conditions
- Type1 Diabetes
- Interventions
- Drug: Insulin glargine new formulation HOE901
- First Posted Date
- 2013-04-23
- Last Posted Date
- 2013-08-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 50
- Registration Number
- NCT01838083
- Locations
- 🇩🇪
Investigational Site Number 276001, Neuss, Germany
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2013-03-18
- Last Posted Date
- 2016-10-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 100
- Registration Number
- NCT01812707
- Locations
- 🇯🇵
Investigational Site Number 392001, Shinjuku-Ku, Japan
🇯🇵Investigational Site Number 392003, Suita-Shi, Japan
🇯🇵Investigational Site Number 392002, Koganei-Shi, Japan
Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2013-02-26
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 350
- Registration Number
- NCT01798706
- Locations
- 🇧🇬
Investigational Site Number 100002, Plovdiv, Bulgaria
🇺🇸Investigational Site Number 840016, Salisbury, North Carolina, United States
🇩🇪Investigational Site Number 276007, Pohlheim, Germany
Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2015-01-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 316
- Registration Number
- NCT01795183
- Locations
- 🇨🇳
Sanofi-Aventis Administrative Office, Beijing, China
Pharmacokinetic of Alirocumab SAR236553 (REGN727) Administered Subcutaneously at 3 Different Injection Sites in Healthy Subjects
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2013-08-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 60
- Registration Number
- NCT01785329
- Locations
- 🇬🇧
Investigational Site Number 826001, London, United Kingdom
To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: intravenous placeboDrug: subcutaneous placebo
- First Posted Date
- 2013-01-15
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 202
- Registration Number
- NCT01768572
- Locations
- 🇺🇸
Investigational Site Number 840033, Fort Lauderdale, Florida, United States
🇺🇸Investigational Site Number 840150, Lansing, Michigan, United States
🇺🇸Investigational Site Number 840022, Dallas, Texas, United States
Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: Insulin glulisine QDDrug: Insulin glulisine TIDDrug: Insulin Glargine (Mandatory background drug)
- First Posted Date
- 2013-01-15
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 894
- Registration Number
- NCT01768559
- Locations
- 🇺🇸
Investigational Site Number 840030, Staten Island, New York, United States
🇺🇸Investigational Site Number 840042, Tempe, Arizona, United States
🇺🇸Investigational Site Number 840036, Nampa, Idaho, United States
Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2014-12-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 100
- Registration Number
- NCT01767714
- Locations
- 🇨🇳
Investigational Site Number 156001, Beijing, China
🇨🇳Investigational Site Number 156003, Beijing, China
🇨🇳Investigational Site Number 156020, Chongqing, China